
Available online at www.sciencedirect.com

Pharmacology & Therapeutics  
www.elsevier.com/locate/pharmthera

Pharmacology & Therapeutics 108 (2005) 257–268

Associate editor: P. Molenaar

# Emerging concepts and therapeutic implications of β-adrenergic receptor subtype signaling

Ming Zheng${}^{a,b}$, Weizhong Zhu${}^{c}$, Qide Han${}^{a,b}$, Rui-Ping Xiao${}^{a,b,c,*}$

${}^{a}$Institute of Cardiovascular Sciences, Peking University, Beijing 100083, People’s Republic of China  
${}^{b}$Institute of Molecular Medicine, Peking University, Beijing 100871, People’s Republic of China  
${}^{c}$Laboratory of Cardiovascular Science, Gerontology Research Center, National Institute on Aging, NIH, Baltimore, MD 21224, USA

## Abstract

The stimulation of β-adrenergic receptor (βAR) plays a pivotal role in regulating myocardial function and morphology in the normal and failing heart. Three genetically and pharmacologically distinct βAR subtypes, β₁AR, β₂AR, and β₃AR, are identified in various types of cells. While both β₁AR and β₂AR, the predominant βAR subtypes expressed in the heart of many mammalian species including human, are coupled to the Gₛ-adenyl cyclase-cAMP-PKA pathway, β₂AR dually activates pertussis toxin-sensitive Gᵢ proteins. During acute stimulation, β₂AR-Gᵢ coupling partially inhibits the Gₛ-mediated positive contractile and relaxant effects via a Gᵢ-Gβγ-phosphoinositide 3-kinase (PI3K)-dependent mechanism in adult rodent cardiomyocytes. More importantly, persistent β₁AR stimulation evokes a multitude of cardiac toxic effects, including myocyte apoptosis and hypertrophy, via a calmodulin-dependent protein kinase II (CaMKII)-, rather than cAMP-PKA-, dependent mechanism in rodent heart in vivo and cultured cardiomyocytes. In contrast, persistent β₂AR activation protects myocardium by a cell survival pathway involving Gᵢ, PI3K, and Akt. In this review, we attempt to highlight the distinct functionalities and signaling mechanisms of these βAR subtypes and discuss how these subtype-specific properties of βARs might affect the pathogenesis of congestive heart failure (CHF) and the therapeutic effectiveness of certain β-blockers in the treatment of congestive heart failure.

© 2005 Published by Elsevier Inc.

**Keywords:** G protein-coupled receptors; β-Adrenergic receptor subtypes; β-Adrenergic receptor polymorphism; G proteins; PKA; CaMKII; PI3K; Apoptosis; Hypertrophy; Congestive heart failure; β-Blocker therapy

## Contents

1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3. Clinical implications of β-adrenergic receptor subtype signaling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
stimulation in the human heart is able to increase cAMP formation and PKA-dependent phosphorylation of intracellular regulatory proteins (PLB, TnI, and C protein), for a given elevation in cAMP production or PKA activation, the β₂AR-induced protein phosphorylation or positive inotropic effect is significantly smaller compared with that induced by β₁AR stimulation (Kaumann et al., 1996, 1998, 1999). In rat and canine cardiomyocytes, β₂AR-mediated augmentation in cAMP is apparently dissociated with its contractile response (Xiao et al., 1994; Altschuld et al., 1995; Kuznetsov et al., 1995; Zhou et al., 1997). More ironically, in mouse cardiomyocytes, β₂AR-induced cAMP formation excites a very minor positive inotropic effect (Xiao et al., 1999). Thus, β₂AR-stimulated cAMP signaling is functionally compartmentalized, while β₁AR-activated cAMP signaling is more diffusible in the cardiac myocytes of many mammalian species, such as human, rat, mouse and dog.

Recent advances in transgenic and gene targeted knockout mouse models, together with in vivo and in vitro physiological and pharmacological measurements, have provided well-controlled experimental systems to further dissect the signaling and functional roles of each βAR subtype in regulating myocardial morphology and functional performance in the normal and failing heart. Among many elegant studies, the work by Milano et al. (1994) has attracted considerable attention in the field of cardiovascular biology and medicine. Cardiac-specific overexpression of the human β₂AR at 100- to 200-fold in mice markedly enhanced cardiac contractility even in the absence of β-agonist, without obvious pathological consequence at the age of 12 months (Milano et al., 1994). This observation was initially interpreted to indicate that the overexpression of βAR might hold great promise to treat heart failure via enhancing the contractility of the failing heart (Milano et al., 1994). Five years later, however, studies in mice with modest (~15-fold) cardiac-specific overexpression of the human β₁AR revealed strikingly different phenotypes, including dilated cardiomyopathy, severe cardiac remodeling, and premature death (Engelhardt et al., 1999; Bisognano et al., 2000). These phenotypic characteristics are similar to those in transgenic mice with cardiac-specific overexpression of Gαₛ (5-fold; Iwase et al., 1996), but markedly different from those, discussed above, in the transgenic mice overexpressing cardiac β₂AR (Milano et al., 1994).

Although studies on βAR transgenic models are fruitful, the overexpression of an individual βAR subtype might cause multiple compensatory alterations in the animal, thus complicating the interpretation. To better dissect the distinct functional and signaling properties of β₁AR versus those of β₂AR, Kobilka and colleagues developed gene-targeted mice lacking β₁AR (β₁AR KO) or β₂AR(β₂ARKO) or both (β₁β₂ DKO; Rohrer et al., 1996, 1999; Chruscinski et al., 1999). Remarkably, catecholamine stimulation fails to induce any cardiac inotropic or chronotropic response in β₁AR KO mice (Rohrer et al., 1996), whereas it produces a full cardiac response in β₂AR KO mice (Chruscinski et al.,

1999). These studies on βAR subtype KO mice imply that β₁AR plays a predominant role in catecholamine-mediated regulation of heart rate and myocardium contractility, even though β₂AR constitutes 20–30% of the total cardiac βARs. In this regard, βAR-induced positive contractile response in human heart is also predominantly mediated by β₁AR stimulation, although β₂AR causes a significant positive inotropic effect (Brodde, 1991; Kaumann et al., 1996, 1999).

Altogether, pharmacological and genetic manipulations of the β₁AR or β₂AR system not only reveal distinctly different functional roles of these βAR subtypes in the heart, but also raise a fundamental question as to why β₁AR and β₂AR are coexpressed in cardiomyocytes if β₁AR is sufficient to fulfill β-adrenergic modulation of cardiac performance.

### 2.2. Dual coupling to \(G_i\) and \(G_s\) of \(\beta_2AR\) but not \(\beta_1AR\)

The failure of \(\beta_2AR\) to produce a proportional contractile response in the heart in rodent and canine hearts is mainly because of a crucial difference between \(\beta_1AR\) and \(\beta_2AR\) in their G protein coupling. In 1995, we demonstrated that stimulation of \(\beta_2AR\) but not \(\beta_1AR\) activates \(G_i\) proteins in adult rat cardiac myocytes, while both \(\beta AR\) subtypes are able to stimulate the classic \(G_s-AC-cAMP-PKA\) signaling pathway (Fig. 1; Xiao et al., 1995). This notion was confirmed in HEK293 cells in 1997 (Daaka et al., 1997), more importantly, in the human heart in 2000 (Kilts et al., 2000). The additional \(G_i\) coupling qualitatively and quantitatively modifies the outcome of the \(G_s\) signaling, while exhibiting important cardiac protective effects (see below).

![Diagram](attachment:Figure_1.png)

Fig. 1. Subtype-specific signaling pathways of cardiac \(\beta ARs\). The dual coupling of \(\beta_2AR\) to \(G_i\) proteins activates the \(G_{i\beta\gamma}-PI3K-Akt\) pathway, which, in turn, leads to functional localization and inhibition of the \(G_s-AC-cAMP-PKA\) signaling and protects cardiomyocytes against apoptosis. In contrast, \(\beta_1AR\) couples exclusively to \(G_s\), which activates the \(G_s-AC-cAMP-PKA\) pathway, resulting in positive inotropic and relaxant effects. The newly identified, PKA-independent activation of CaMKII is necessary and sufficient in mediating persistent \(\beta_1AR\) stimulation-induced myocyte apoptosis, perhaps cardiac hypertrophy as well. Emerging evidence suggests that cardiac \(\beta_3AR\) might also couple to \(G_i\), in addition to \(G_s\), resulting in the activation of the NOS-NO signaling pathway, which negatively regulates cardiac contractility (PTX, pertussis toxin).

During acute receptor stimulation, the β₂AR–Gᵢ coupling activates phosphoinositide 3-kinase (PI3K), which, in turn, mediates compartmentalization of the concurrent Gₛ-cAMP signaling, thereby negating β₂AR-induced PLB phosphorylation and the positive inotropic and lusitropic responses in rat and canine ventricular myocytes (Kuschel et al., 1999a, 1999b; Jo et al., 2002; Fig. 1). During prolonged receptor stimulation, the β₂AR–Gᵢ coupling evokes multiple Gₛ-independent signaling pathways, including the activation of MAPKs (Daaka et al., 1997; Communal et al., 2000; Shizukuda & Buttrick, 2002) and PI3K–Akt (Chesley et al., 2000; Zhu et al., 2001), resulting in cardiac protective effects (Fig. 1). It has been shown that PKA-dependent β₂AR phosphorylation switches the receptor G protein coupling from Gₛ to Gᵢ in HEK 293 cells (Daaka et al., 1997) and rat cardiac myocytes (Zou et al., 1999), which might desensitize the receptor-mediated inotropic response while enhancing its cardiac protective effect during prolonged agonist stimulation.

### 2.3. Switch from PKA- to calmodulin-dependent protein kinase II-dependent signaling during sustained β₁AR activation

The traditional view on cardiac βAR signal transduction is that, under physiological conditions, catecholamines induce positive inotropic, lusitropic, and chronotropic responses through the β₁AR-mediated activation of the Gₛ–AC–cAMP–PKA pathway (Fig. 1). Subsequently, PKA leads to the phosphorylation of a panel of key target proteins involved in cardiac excitation–contraction coupling, including sarcolemmal L-type Ca²⁺ channels, the sarcoplasmic reticulum membrane protein PLB, and some contractile myofilament proteins such as troponin I (TnI) and C protein. Pharmacological studies have suggested that β₁AR-induced cardiomyocyte apoptosis is also likely mediated by the cAMP–PKA pathway (Communal et al., 1999; Zaugg et al., 2000). Thus, it was thought that the functional consequences of either acute or persistent β₁AR activation might be exclusively mediated by the classic Gₛ–AC–cAMP–PKA signaling cascade.

This perception has been, however, challenged by more recent studies. In particular, persistent β₁AR activation augments myocyte contractility and intracellular Ca²⁺ transients via Ca²⁺/calmodulin-dependent protein kinase II (CaMKII) signaling, independently of the cAMP–PKA pathway in adult rat cardiac myocytes (Fig. 1). This emerging β₁AR signaling paradigm is based on following lines of evidence. First, the inhibition of the PKA pathway cannot block sustained β₁AR stimulation-mediated increases in myocyte contraction and Ca²⁺ transients, whereas the inhibition of CaMKII activation by specific inhibitors or a dominant-negative mutant fully abolishes the effects of sustained β₁AR stimulation without affecting those excited by acute β₁AR activation (Wang et al., 2004). In contrast, the inhibition of PKA but not CaMKII prevents acute β₁AR signaling-mediated positive inotropic and lusitropic effects (Wang et al., 2004). Second, tracking cAMP production and CaMKII activation over an extended time course (24 hr) reveals that a progressive and persistent CaMKII activation is accompanied by a rapid desensitization of the cAMP–PKA signaling, consistent with the previous notion (Hausdorff et al., 1990) indicating that β₁AR signaling undergoes a time-dependent switch from the PKA-dominant pathway to the CaMKII-dominant pathway after receptor stimulation (Wang et al., 2004; Fig. 1).

Likewise, sustained β₁AR stimulation markedly increases cardiomyocyte apoptosis via a CaMKII-, rather than PKA-, dependent mechanism (Fig. 1). In 2 genetically well-defined β₁AR experimental settings, that is, myocytes from β₂AR KO mice or those from β₁β₂ DKO in conjunction with adenoviral gene transfer of β₁AR, the apoptotic effects of persistent β₁AR stimulation are fully prevented by inhibiting CaMKII activity, but not by blocking PKA activation (Zhu et al., 2003). Furthermore, the overexpression of a cardiac CaMKII isoform, CaMKII-δC, markedly aggravates the β₁AR-induced apoptotic death of cardiomyocytes (Zhu et al., 2003). Our recent studies have shown that enhanced CaMKII activation is both necessary and sufficient for β₁AR-mediated apoptotic heart cell death. Moreover, β₁AR-activated CaMKII signaling, instead of the PKA pathway, is essentially involved in CHF-associated fetal gene expression (Bristow et al., personal communication) and catecholamine-induced cardiomyocyte hypertrophy (Morisco et al., 2000). Thus, the time-dependent β₁AR signaling switch from the PKA-dominant pathway to the CaMKII-dominant pathway underscores that CaMKII constitutes a determinant of clinically important heart disease phenotypes, and that CaMKII inhibition might offer a promising approach for targeting adverse myocardial remodeling in the context of enhanced β₁AR signaling, as is the case for CHF. This perception has been recently validated by the fact that CaMKII inhibition via cardiac-specific overexpression of a CaMKII peptide inhibitor in transgenic mice significantly prevents maladaptive remodeling and cardiac contractile dysfunction from excessive βAR stimulation or myocardial infarction (Zhang et al., 2005). The notion that enhanced CaMKII activation mediates the detrimental effects of chronically elevated βAR signaling is consistent with the phenotypes of heart failure and premature death in transgenic mice overexpressing cardiac CaMKII-δC (Zhang et al., 2003) and is supported by a central role of CaMKII signaling pathway in insulin factor-induced apoptosis in several naive cell lines (Wright et al., 1997; Fladmark et al., 2002).

In supporting the cardiac toxic effects of persistent β₁AR signaling, levels of plasma norepinephrine, an endogenous β₁AR agonist, and an active anti-β₁AR antibody (Limas et al., 1989) have been directly associated with CHF mortality in humans (Hagar & Rahimtoola, 1995). Experimentally elevating the active anti-β₁AR antibody is sufficient to trigger cardiomyopathy and CHF in animal models (Jahns et al.,
2004). Despite many unanswered questions with respect to the exact signaling pathways responsible for $\beta_{1}$AR-mediated cardiac toxic effects, emerging evidence points to $\beta_{1}$AR-activated CaMKII as a major player in the progress of cardiac pathological remodeling, particularly myocyte hypertrophy and apoptosis, and ultimately contributing to myocardial contractile dysfunction and the progression of CHF.

It remains highly controversial as to whether chronic activation of the cAMP–PKA pathway causes cardiac detrimental consequences. For instance, enhanced signaling of the AC–cAMP–PKA pathway by overexpressing adenylyl cyclase type V or VI does not produce CHF, but unexpectedly alleviates CHF in the G$\alpha_{q}$-overexpressing mouse (Gao et al., 1999; Tepe et al., 1999; Roth et al., 2002). More ironically, enhanced $\beta_{2}$AR stimulation by agonists or modest overexpression of the receptor, while marked elevating cAMP–PKA signaling, exhibits beneficial effects in several CHF models (Dorn et al., 1999; Liggett et al., 2000; Ahmet et al., 2004). Nevertheless, the cardiac-specific overexpression of PKA catalytic subunit by as modest as 2.4-fold or the overexpression of G$\alpha_{s}$ by 5-fold leads to CHF phenotype in mice (Antos et al., 2001; Vatner et al., 2000). These paradoxical observations challenge the conventional wisdom that the cAMP–PKA pathway is solely responsible for $\beta_{1}$AR-induced cardiac detrimental effects. Resolving these paradoxes should reveal valuable etiological insights and novel therapeutic targets for CHF.

### 2.4. Persistent $\beta_{2}AR$ stimulation protects cardiomyocytes by a $G_{i}$–phosphoinositide 3-kinase–Akt dependent mechanism

The aforementioned studies have provided compelling evidence that persistent $\beta_{1}$AR activation is toxic to cardiomyocytes in vivo and in vitro. However, the scenario of persistent $\beta_{2}$AR stimulation is strikingly different. In particular, the stimulation of $\beta_{2}$AR in adult mouse cardiomyocytes lacking native $\beta_{1}$AR protects myocytes against catecholamine-induced myocyte apoptosis in vivo (Zhu et al., 2001; Patterson et al., 2004). These studies performed in the “genetically pure $\beta_{2}$AR systems” are, in principle, consistent with earlier pharmacological studies that the blockade of $\beta_{1}$AR but not $\beta_{2}$AR prevents catecholamine-, hypoxia-, or reactive oxygen species (ROS)-induced apoptotic death in both neonatal and adult rat cardiomyocytes (Communal et al., 1999; Chesley et al., 2000; Zaugg et al., 2000). The cardiac beneficial effects of persistent $\beta_{2}$AR signaling have been further confirmed in recent in vivo studies: Selective activation of $\beta_{2}$AR by fenoterol for 8 weeks exerts a clear antiapoptotic effect and improves cardiac performance in an ischemic rat heart failure model (Ahmet et al., 2004). The opposite effects of $\beta_{1}$AR and $\beta_{2}$AR on the fate of cardiomyocytes might contribute, at least in part, to the markedly different outcomes of genetic manipulations of these $\beta$AR subtypes in mouse genetic models (Milano et al., 1994; Dorn et al., 1999; Engelhardt et al., 1999; Liggett et al., 2000; Bisognano et al., 2000).

The cardiac protective effect of persistent $\beta_{2}$AR signaling is largely mediated by the $\beta_{2}$AR–$G_{i}$ coupling, which, in turn, activates a cell survival pathway sequentially involving $G_{i\beta\gamma}$, PI3K, and Akt (Fig. 1). This perception is corroborated by following lines of evidence. First, $\beta_{2}$AR, but not $\beta_{1}$AR, activates a $G_{i}$–$G_{\beta\gamma}$–PI3K–Akt cell survival-signaling pathway, and the inhibition of this pathway converts $\beta_{2}$AR signaling from survival to apoptotic (Zhu et al., 2001). Second, in cultured adult rat myocytes, $\beta_{2}$AR blockade enhances the apoptotic effect of norepinephrine in a PTX-sensitive manner, suggesting that the $\beta_{2}$AR protective effect is $G_{i}$-dependent (Communal et al., 1999). Third, the effect of $\beta_{2}$AR stimulation in protecting cardiomyocytes from hypoxia and ROS is also attributable to the $G_{i}$–PI3K–Akt pathway (Chesley et al., 2000). Thus, the $\beta_{2}$AR–$G_{i}$–$G_{\beta\gamma}$–PI3K–Akt signaling cascade counteracts $\beta_{1}$AR-mediated apoptosis and protects myocytes against a wide range of apoptotic insults.

The extracellular signal-regulated protein kinases (ERK1/2) and p38 MAPK are also implicated in $\beta_{2}$AR–$G_{i}$-mediated antiapoptotic signaling (Communal et al., 2000; Shizukuda & Buttrick, 2002). We and others have, however, provided evidence that argues against any essential role p38 MAPK in regulating myocyte apoptosis. The activation of p38 MAPKs by the transgenic overexpression of activated mutants of upstream kinases MKK3bE and MKK6bE neither induces nor suppresses cardiomyocyte apoptosis (Liao et al., 2001). Given the fact that p38 MAPK plays an essential role in cardiac hypoxia- and ischemia-induced cardiomyocyte injury and apoptosis (Bogoyevitch et al., 1996; Sugden & Clerk, 1998; Nakano et al., 2000; Zheng et al., 2005), it is unlikely that $\beta_{2}$AR-mediated antiapoptotic effect is attributed to p38 MAPK signaling.

### 2.5. Heterodimerization of $\beta_{1}AR$ and $\beta_{2}AR$

Increasing evidence suggests that GPCRs may exist as both homodimers or heterodimers (Hebert et al., 1996; Jones et al., 1998). The physical interaction of GPCRs within or among different families creates new entities endowed with distinctly different ligand-binding and signaling properties. For example, $\beta_{1}$AR and $\beta_{2}$AR subtypes form heterodimers in HEK 293 cells (Lavoie et al., 2002; Mercier et al., 2002), and the heterodimerization of these $\beta$AR subtypes inhibits $\beta_{2}$AR internalization and its ability to activate ERK1/2 MAPK signaling (Lavoie et al., 2002). The coexpression of both $\beta_{1}$AR and $\beta_{2}$AR in HEK293 cells also reduces the high affinity binding of subtype-selective ligands, as compared with the expression of a single subtype in those cells (Lavoie & Hebert, 2003).

Because the heterodimerization of $\beta_{1}$AR and $\beta_{2}$AR alters both the functional and signaling properties of these receptors, the dimeric $\beta_{1}$AR/$\beta_{2}$AR should be considered as pharmacologically and functionally distinct population of $\beta$ARs. Thus, many well-established paradigms for $\beta$AR signaling and functionality need to be revisited in the
context of the coexistence of multiple receptor subtypes and their homo- and heterodimers. In addition, it remains to be explored whether β<sub>1</sub>AR and β<sub>2</sub>AR undergo heterodimerization in cardiomyocytes and, if so, to determine the potential physiological or pathological relevance of their heterodimerization.

3. Clinical implications of β-adrenergic receptor subtype signaling

3.1. Possible causal relation between β-adrenergic receptor subtype signaling and the pathogenesis of heart failure

A possible causal relation between βAR stimulation and the pathogenesis of CHF have evolved progressively during the past 3 decades. Because a hallmark of CHF is the diminished cardiac contractile performance, the early prevalent view was that the reduced βAR contractile support is a causal factor for the progression of heart failure (Braunwald & Bristow, 2000). However, clinical administration of βAR agonists unexpectedly increased the mortality of patients with CHF, despite the short-term gain of inotropic support. Paradoxically, some βAR antagonists were able to improve cardiac function and decrease the mortality of patients with CHF (Bristow, 2000). Furthermore, over the past couple of decades, physician-scientists have appreciated that CHF is, in fact, associated with elevated circulating catecholamine levels and hyperadrenergic drive. There is a close positive relation between levels of circulating catecholamines (especially norepinephrine) and adverse clinical outcomes of CHF patients (Cohn et al., 1984). The infusion of catecholamines causes cardiomyopathy and remodeling, ultimately leading to heart failure in various animal models (Braunwald & Bristow, 2000). The current perception is that hyperadrenergic drive initially activates a multitude of compensatory mechanisms to maintain normal cardiac output; persistent receptor stimulation then causes desensitization and downregulation of βARs, particularly β<sub>1</sub>AR subtype, and eventually, cardiac pathological remodeling and heart failure (Lohse et al., 2003). This conceptual breakthrough forms the rationale for β-blocker therapy for CHF.

As discussed above, the essence of cardiac βAR signaling is subtype specific and time dependent. In this regard, there is a large body of evidence that the cardiac toxic effects of catecholamines are mediated mainly, if not exclusively, by persistent β<sub>1</sub>AR stimulation. First, the administration of isoproterenol, a βAR agonist, exhibits protective, rather than detrimental, consequences in vivo or in cultured cardiomyocytes from mice lacking native β<sub>1</sub>AR (Zhu et al., 2001; Patterson et al., 2004). Second, enhanced β<sub>1</sub>AR signaling by either receptor overexpression or agonist stimulation consistently evokes cardiac detrimental effects, as manifested by myocyte apoptosis, overall cardiac hypertrophy and fibrosis, and heart failure (Communal et al., 1999; Engelhardt et al.,

1999; Bisognano et al., 2000; Zhu et al., 2003). Third, clinical and basic bench studies have demonstrated that autoimmune antibodies that react and activate β<sub>1</sub>AR are sufficient to induce cardiomyopathy and CHF in humans and animal models (Limas et al., 1989; Jahns et al., 2004). Furthermore, β<sub>1</sub>AR selective blockers such as metoprolol and bisoprolol exhibit clear-cut beneficial effects in improving the cardiac function and survival in CHF patients (Bristow et al., 2004; Greenberg, 2004) and animal models (Harding et al., 2001; Morita et al., 2002). Thus, the current consensus is that sustained β<sub>1</sub>AR stimulation serves as a causal factor of CHF, while β<sub>2</sub>AR activation may actually be protective for the failing heart.

3.2. Therapeutic implications of subtype-specific β-adrenergic receptor signaling

Chronologically, βAR blocking agents were categorized into 3 generations: nonselective βAR blocking agents, for example, propranolol and nadolol; β<sub>1</sub>AR-selective blocking agents, for example, metoprolol and bisoprolol; and nonselective (α<sub>1</sub> and β) adrenergic receptor blocking agents, for example, carvedilol and bucindolol Bristow (Bristow, 2000). Over the last several years, a host of clinical trials have been set out to compare the clinical outcomes of β<sub>1</sub>AR-selective such as metoprolol and bisoprolol versus a nonselective βAR blocker, carvedilol. Placebo-controlled mortality trials with carvedilol (Mitra et al., 1994; Krum et al., 1995; Olsen et al., 1995), bisoprolol (CIBIS-II Investigators and Committees, 1999), and metoprolol (MERIT-HF Study Group, 1999; Hjalmarson et al., 2000) have demonstrated a long-term reduction in total mortality, cardiovascular mortality, sudden cardiac death, and death due to the progression of CHF in patients with NYHA class II–IV. Interestingly, both β<sub>1</sub>AR-selective and nonselective β-blockers substantially reduce morbidity and mortality in patients with CHF to a similar extent (Mitra et al., 2000; Poole-Wilson et al., 2003). Because β<sub>1</sub>AR-selective blockers are equally effective in treating CHF, it is plausible that β-blocker therapy for CHF might be mainly mediated by antagonizing β<sub>1</sub>AR cardiac toxic effects. However, a recently published COMET study has shown a 17% advantage of carvedilol (25 mg twice daily) over immediate-release metoprolol (50 mg twice daily) in reducing the mortality in CHF patients (Poole-Wilson et al., 2003). Despite the long-term and large scope (3029 patients) nature of the COMET trial, this study was inappropriately designed in the choice of dose and dosage regimen, thus significantly compromising its weight in evaluating the effectiveness of β<sub>1</sub>AR-selective versus that of nonselective β-blockers (Bristow et al., 2004).

Multiple mechanisms might be involved in the cardiac beneficial effects of β-blockers in the failing heart. Among these, the delay or amelioration of β<sub>1</sub>AR-mediated cardiac toxic effects, including myocyte hypertrophy and apoptosis, may play a central role. Other mechanisms have also been

implicated in β-blocker therapy. These include the restoration of cardiac excitation–contraction coupling and Ca²⁺ handling machineries (Freeman et al., 2001; Reiken et al., 2001, 2003), anti-ischemic action of β-blockers by reducing heart rate and improving cardiac perfusion and metabolism, and antiarrhythmic effects, thus reducing the incidence of sudden death in CHF patients (Lohse et al., 2003). Nevertheless, the exact mechanism underlying the beneficial effects of β-blockers in improving the function of the failing heart merits further basic and clinical investigations.

### 3.3. Potential impact of β-adrenergic receptor subtype polymorphisms on the development of CHF

Recent progress in human population genetics have revealed an important linkage between certain polymorphisms (occurrence with a frequency >1% in a population) of βAR genes and clinical phenotypes in terms of predisposition, prognosis, and response to β-blocker therapy in patients with CHF. Two common polymorphisms in the β₁AR, Ser49Gly and Arg389Gly, and 3 in the β₂AR, Arg16Gly, Gln27Glu, and Thr164Ile, have been identified and functionally characterized (Small et al., 2003). In vitro and in vivo studies have shown that most of the polymorphic βARs exhibit either enhanced or reduced signaling efficiency relative to their allelic counterparts. For instance, when overexpressed, the β₁AR-Arg389 (a glycine in transgenic mice is substituted by an arginine at amino acid position 389) variant leads to sensitized agonist-mediated receptor stimulation in fibroblast cell lines (Mason et al., 1999). Moreover, cardiac-targeted transgenic expression of β₁AR-Arg389 in mice exhibits reduced receptor–agonist signaling in activating adenylyl cyclase, abnormal expression of fetal and hypertrophy genes, and decreased cardiac contractility compared with β₁AR-Gly389 hearts (Kass, 2003; Mialet Perez et al., 2003). This phenotype is, to a large extent, recapitulated in homozygous, end-stage failing human hearts. Thus, it is speculated that the human β₁AR-Arg389 variant predisposes to heart failure because of the hyperactive signaling of the receptor, leading to depressed receptor coupling and ventricular dysfunction.

Among the aforementioned 3 β₂AR polymorphisms, the Ile164 variant displays markedly blunted signaling efficiency in response to agonist stimulation in vitro (Green et al., 1993) and in the overexpression transgenic mouse model (Turki et al., 1996). It is noteworthy that the prognosis of CHF patients with β₂AR-Ile164 is much worse than that of patients with the wild-type β₂AR-Thr164 (Liggett et al., 1998), consistent with the general notion that β₂AR activation is cardiac protective (Ahmet et al., 2004; Patterson et al., 2004). In light of the opposing functional roles of β₁AR and β₂AR in regulating cardiomyocyte fate and morphology, it is not surprising to find that the particular case of “gain-of-function” of the β₁AR-Arg389 variant, as well as the “loss-of-function” of β₂AR-Thr164 variant, is more likely associated with an increased risk of progression and worse prognosis of CHF patients. However, it is noteworthy that this is not always the case for all identified β₁AR or β₂AR polymorphisms (see Kirstein & Insel, 2004; Leineweber et al., 2004, for recent reviews).

#### 3.4. Enhancing cardiac protective β₂AR signaling as a potential therapy for congestive heart failure

In many types of CHF, the reduction in β₁AR and β₂AR inotropic responses is often accompanied by an up-regulation of Gᵢ (Eschenhagen et al., 1992; Bohm et al., 1994; Xiao et al., 2003) and a selective down-regulation of β₁AR (Bristow et al., 1986; Kiuchi et al., 1993; Xiao et al., 2003). Based on above discussions, it is reasonable to assume that the selective down-regulation of β₁AR and the up-regulation of β₂AR–Gᵢ signaling in the failing heart from humans (Gong et al., 2002; Harding & Gong, 2004) and animal models (Xiao et al., 2003) may represent cardiac adaptive mechanisms to protect myocytes against apoptosis and consequently ameliorate cardiomyopathy and contractile dysfunction. Several studies have provided supporting evidence for this perception. Moderate overexpression of cardiac β₂AR (~30-fold) restores ventricular function and cardiac morphology in CHF mice with cardiac-specific overexpression of Gαq (Dorn et al., 1999). Moreover, β₂AR stimulation by fenoterol restores the contractile response of myocytes from spontaneous hypertensive rat failing hearts (Xiao et al., 2003) and markedly protects myocardium from ischemia-induced hypertrophy and apoptosis and improves the performance of the ischemic failing heart (Ahmet et al., 2004). However, the exact mechanism underlying fenoterol-mediated beneficial effects in the failing heart merits future investigation. In this regard, our preliminary studies have shown that fenoterol, the apparent β₂AR–Gₛ-selective agonist, not only restores the diminished β₂AR positive inotropic effect but also exhibits a potent antiapoptotic effect in culture mouse and rat cardiomyocytes in a PTX-insensitive manner (Zhu et al., unpublished data), as is the case in vivo in the rat ischemic heart failure model (Ahmet et al., unpublished data), suggesting that fenoterol protects cardiomyocytes against apoptosis via a Gᵢ-independent mechanism. Furthermore, the cardiac protective effects of chronic β₂AR stimulation with fenoterol have synergy with β₁AR blockade by metoprolol in the ischemic rat heart failure model (Ahmet et al., unpublished data; also see below). Nevertheless, future studies are required to delineate the mechanism responsible for fenoterol-mediated, Gᵢ-independent cardiac protection.

It is widely accepted that prolonged agonist exposure leads to a decrease in βAR responsiveness, that is, desensitization. βARK1 (also known as GPCR kinase 2, GRK2) plays a central role in agonist-induced desensitization of both β₁AR and β₂AR and is crucially involved in the development of various etiologies of heart failure (Williams et al., 2004; Tachibana et al., 2005). Importantly, inhibiting

βARK1-mediated desensitization of βAR by βARK-ct restores the diminished βAR responsiveness and largely reverses the impaired myocardial contractile performance in mouse heart failure models (Rockman et al., 1998; Harding et al., 2001). Similar results were observed in cultured failing human cardiomyocytes (Williams et al., 2004). The beneficial effects of the inhibition of βARK1 by βARK-ct is largely mediated by enhancing β₂AR signaling, because β₁AR blockade markedly augments, rather than compromises, the beneficial effects of βARK-ct in improving survival and cardiac performance (Harding et al., 2001). Conversely, the up-regulation of βARK1 precedes and is thought to participate in the pathogenesis of CHF (Ungerer et al., 1994; Anderson et al., 1999; Cho et al., 1999). Consistent with this perception, transgenic mice overexpressing cardiac βARK1 manifest many pathological alterations observed in CHF, including dysfunction of βAR signaling and cardiac hypertrophy (Koch et al., 1995; Korzick et al., 1997). Based on these studies, we envision that a combination of β₁AR blockade with β₂AR stimulation might open a more effective therapeutic avenue for the treatment of CHF.

However, β₂AR–Gᵢ signaling offsets β₂AR–Gₛ-induced contractile response in the normal heart (Jo et al., 2002) and negates both β₁AR- and β₂AR-mediated positive inotropic effects in the failing heart (Sato et al., 2004). Interestingly, the inhibition of Gᵢ signaling or the disruption of the association of βARs with PI3K restores βAR inotropic response in a variety of CHF models (Brown & Harding, 1992; Kompa et al., 1999; Xiao et al., 2003) and markedly ameliorates the development of CHF (Nienaber et al., 2003). Thus, exaggerated β₂AR–Gᵢ–PI3K signaling might contribute to the contractile dysfunction of the failing heart, despite its antiapoptotic effect.

For the enhancement of β₂AR signaling to serve as a potential therapy for CHF, the current challenge is how to retain β₂AR–Gᵢ-mediated antiapoptotic effect, while avoiding its negative inotropic effect. Recent studies have demonstrated that CHF-associated increase in β₂AR–Gᵢ signaling is responsible for the blunted β₁AR- as well as β₂AR-mediated contractile support and the overall contractile dysfunction, mainly via activating sarcolemmal Na⁺/Ca²⁺ exchanger (NCX) and subsequently depleting sarcoplasmic reticulum Ca²⁺ load (Sato et al., 2004; Xiao & Balke, 2004). Thus, NCX might represent a more specific downstream target of β₂AR signaling for new therapies in the treatment of CHF, via enhancing contractile support without compromising the Gᵢ-PI3K-mediated antiapoptotic effect (Fig. 1).

### 3.5. Up-regulation of β₃AR in congestive heart failure

While β₃AR is primarily expressed in adipose tissues, it is also expressed in cardiomyocytes. Unlike the stimulation of β₁AR and β₂AR, the activation of β₃AR leads to negative regulation of cardiac contractility via the receptor-coupled Gᵢ signaling (Gauthier et al., 1996), which increases NO production via the activation of endothelial constitutive NO synthase (NOS) in human cardiac myocytes (Gauthier et al., 1998; Fig. 1). Notably, the expression of β₃AR is increased by 2- to 3-fold in CHF (Moniotte et al., 2001; Morimoto et al., 2004). It is presently unknown whether the increased β₃AR expression exerts an antiapoptotic effect, similar to that of β₂AR, thus protecting the failing heart. On the other hand, the up-regulation of β₃AR is expected to cause a greater cardiac contractile depression, thereby contributing to the contractile dysfunction in CHF. The potential pathophysiological relevance of the CHF-associated up-regulation of β₃ARs awaits further study.

## 4. Concluding remarks

Recent progress in cardiac βAR signaling is marked by discoveries on subtype-specific and time-dependent signaling mechanisms, receptor heterodimerization, dual G protein coupling, and several new intracellular signaling pathways. These advances have greatly deepened our understanding of the causal relation between βAR stimulation and the pathogenesis of CHF. The distinct β₁AR and β₂AR biology and signaling properties also shed new light on the clinical variation in the effectiveness of β-blockers and the markedly different impact of βAR subtype polymorphisms on the progression of CHF. The opposing functional roles of β₁AR and β₂AR in the progression of CHF provide the rationale for a combination of β₁AR blockade with β₂AR activation as a new prevention and intervention strategy for the treatment of CHF.

## Acknowledgments

The authors would like to thank Dr. H. Cheng for critical comments and discussions. This work is supported by the Chinese National Natural Science Foundation (30100215), Peking University 985 Project, Chinese National Key Project 973 (G2000056906), and Chinese Young Investigator Award (30225036), and, in part, by NIH intramural research grant (WZW and RPX).

## References

Ahmet, I., Krawczyk, M., Heller, P., Moon, C., Lakatta, E. G., & Talan, M. I. (2004). Beneficial effects of chronic pharmacological manipulation of β-adrenoreceptor subtype signaling in rodent dilated ischemic cardiomyopathy. *Circulation* 110, 1083–1090.

Altschuld, R. A., Starling, R. C., Hamlin, R. L., Hensley, J., Castillo, L., Fertel, R. H., et al. (1995). Response of failing canine and human heart cells to β2-adrenergic stimulation. *Circulation* 92, 1612–1618.

Anderson, K. M., Eckhart, A. D., Willette, R. M., & Koch, W. J. (1999). The myocardial beta-adrenergic system in spontaneously hypertensive heart failure (SHHF) rats. *Hypertension* 33, 402–407.

Antos, C. L., Frey, N., Marx, S. O., Reiken, S., Gaburjakova, M., Richardson, J. A., et al. (2001). Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase A. *Circ Res* 89, 997–1004.

Baker, J. G. (2005). The selectivity of β-adrenoceptor antagonists at the human β₁, β₂ and β₃ adrenoceptors. *Br J Pharmacol* 144, 317–322.

Bisognano, J. D., Weinberger, H. D., Bohlmeier, T. J., Pende, A., Raymonds, M. V., Sastravaha, A., et al. (2000). Myocardial-directed overexpression of the human β₁-adrenergic receptor in transgenic mice. *J Mol Cell Cardiol* 32, 817–830.

Bogoyevitch, M. A., Gillespie-Brown, J., Ketterman, A. J., Fuller, S. J., Ben-Levy, R., Ashworth, A., et al. (1996). Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion. *Circ Res* 79, 162–173.

Bohm, M., Eschenhagen, T., Gierschik, P., Larisch, K., Lensche, H., Mende, U., et al. (1994). Radioimmunochemical quantification of Giα in right and left ventricles from patients with ischaemic and dilated cardiomyopathy and predominant left ventricular failure. *J Mol Cell Cardiol* 26, 133–149.

Braunwald, E., & Bristow, M. R. (2000). Congestive heart failure: fifty years of progress. *Circulation* 102, IV14–IV23.

Bristow, M. R. (2000). Mechanistic and clinical rationales for using β-blockers in heart failure. *J Card Fail* 6, 8–14.

Bristow, M. R., Ginsburg, R., Umans, V., Fowler, M., Minobe, W., Rasmussen, R., et al. (1986). β₁- and β₂-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective β₁-receptor down-regulation in heart failure. *Circ Res* 59, 297–309.

Bristow, M. R., Feldman, A. M., Adams Jr., K. F., & Goldstein, S. (2004). Selective versus nonselective β-blockade for heart failure therapy: are there lessons to be learned from the COMET trial? *J Card Fail* 9, 444–453.

Brodde, O. E. (1988). The functional importance of β₁ and β₂ adrenoceptors in the human heart. *Am J Cardiol* 62, 24C–29C.

Brodde, O. E. (1991). β₁- and β₂-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. *Pharmacol Rev* 43, 203–242.

Brown, L. A., & Harding, S. E. (1992). The effect of pertussis toxin on β-adrenoceptor responses in isolated cardiac myocytes from noradrenaline-treated guinea-pigs and patients with cardiac failure. *Br J Pharmacol* 106, 115–122.

Chesley, A., Lundberg, M. S., Asai, T., Xiao, R. P., Ohtani, S., Lakatta, E. G., et al. (2000). The β₂-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through Gi-dependent coupling to phosphatidylinositol 3′kinase. *Circ Res* 87, 1172–1179.

Cho, M. C., Rao, M., Koch, W. J., Thomas, S. A., Palmiter, R. D., & Rockman, H. A. (1999). Enhanced contractility and decreased β-adrenergic receptor kinase-1 in mice lacking endogenous norepinephrine and epinephrine. *Circulation* 99, 2702–2707.

Chruscinski, A. J., Rohrer, D. K., Schauble, E., Desai, K. H., Bernstein, D., & Kobilka, B. K. (1999). Targeted disruption of the β₂-adrenergic receptor gene. *J Biol Chem* 274, 16694–16700.

Cohn, J. N., Levine, T. B., Olivari, M. T., Garberg, V., Lura, D., Francis, G. S., et al. (1984). Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. *N Engl J Med* 311, 819–823.

Communal, C., Singh, K., Sawyer, D. B., & Colucci, W. S. (1999). Opposing effects of β₁- and β₂-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. *Circulation* 100, 2210–2212.

Communal, C., Colucci, W. S., & Singh, K. (2000). p38 mitogen-activated protein kinase pathway protects adult rat ventricular myocytes against β-adrenergic receptor-stimulated apoptosis. Evidence for Gi-dependent activation. *J Biol Chem* 275, 19395–19400.

Daaka, Y., Luttrell, L. M., & Lefkowitz, R. J. (1997). Switching of the coupling of the β₂-adrenergic receptor to different G proteins by protein kinase A. *Nature* 390, 88–91.

Dixon, R. A., Kobilka, B. K., Strader, D. J., Benovic, J. L., Dohlman, H. G., Frielle, T., et al. (1986). Cloning of the gene and cDNA for mammalian β-adrenergic receptor and homology with rhodopsin. *Nature* 321, 75–79.

Dooley, D. J., Bittiger, H., & Reymann, N. C. (1986). CGP 20712 A: a useful tool for quantitating β₁- and β₂-adrenoceptors. *Eur J Pharmacol* 130, 137–139.

Dorn II, G. W., Tepe, N. M., Lorenz, J. N., Koch, W. J., & Liggett, S. B. (1999). Low- and high-level transgenic expression of β₂-adrenergic receptors differentially affect cardiac hypertrophy and function in Gαq-overexpressing mice. *Proc Natl Acad Sci USA* 96, 6400–6405.

Emorine, L. J., Marullo, S., Briand-Sutren, M. M., Patey, G., Tate, K., Delavier-Klutchko, C., et al. (1989). Molecular characterization of the human β₃-adrenergic receptor. *Science* 245, 1118–1121.

Engelhardt, S., Hein, L., Wiesmann, F., & Lohse, M. J. (1999). Progressive hypertrophy and heart failure in β₁-adrenergic receptor transgenic mice. *Proc Natl Acad Sci USA* 96, 7059–7064.

Eschenhagen, T., Mende, U., Nose, M., Schmitz, W., Scholz, H., Haverich, A., et al. (1992). Increased messenger RNA level of the inhibitory G protein alpha subunit Giα₂ in human end-stage heart failure. *Circ Res* 70, 688–696.

Fladmark, K. E., Brustugun, O. T., Mellgren, G., Krakstad, C., Boe, R., Vintermyr, O. K., et al. (2002). Ca²⁺/calmodulin-dependent protein kinase II is required for microcystin-induced apoptosis. *J Biol Chem* 277, 2804–2811.

Freeman, K., Lerman, I., Kranias, E. G., Bohlmeier, T., Bristow, M. R., Lefkowitz, R. J., et al. (2001). Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. *J Clin Invest* 107, 967–974.

Frielle, T., Collins, S., Daniel, K. W., Caron, M. G., Lefkowitz, R. J., & Kobilka, B. K. (1987). Cloning of the cDNA for the human β₁-adrenergic receptor. *Proc Natl Acad Sci USA* 84, 7920–7924.

Gao, M. H., Lai, N. C., Roth, D. M., Zhou, J., Zhu, J., Anzai, T., et al. (1999). Adenylyl cyclase increases responsiveness to catecholamine stimulation in transgenic mice. *Circulation* 99, 1618–1622.

Gauthier, C., Tavernier, G., Charpentier, F., Langin, D., & Le Marec, H. (1996). Functional β₃-adrenoceptor in the human heart. *J Clin Invest* 98, 556–562.

Gauthier, C., Leblais, V., Kobzik, L., Trochu, J. N., Khandoudi, N., Bril, A., et al. (1998). The negative inotropic effect of β₃-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. *J Clin Invest* 102, 1377–1384.

Gong, H., Sun, H., Koch, W. J., Rau, T., Eschenhagen, T., Ravens, U., et al. (2002). Specific β₂AR blocker ICI 118,551 actively decreases contraction through a Gi-coupled form of the β₂AR in myocytes from failing human heart. *Circulation* 105, 2497–2503.

Green, S. A., Cole, G., Jacinto, M., Innis, M., & Liggett, S. B. (1993). A polymorphism of the human β₂-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. *J Biol Chem* 268, 23116–23121.

Greenberg, B. (2004). Nonselective versus selective β-blockers in the management of chronic heart failure: clinical implications of the carvedilol or Metoprolol European Trial. *Rev Cardiovasc Med* 5, S10–S17.

Hagar, J. M., & Rahimtula, S. H. (1995). Chagas’ heart disease. *Curr Probl Cardiol* 20, 825–924.

Harding, S. E., & Gong, H. (2004). β-Adrenoceptor blockers as agonists: coupling of β₂-adrenoceptors to multiple G-proteins in the failing human heart. *Congest Heart Fail* 10, 181–185.

Harding, V. B., Jones, L. R., Lefkowitz, R. J., Koch, W. J., & Rockman, H. A. (2001). Cardiac βARK1 inhibition prolongs survival and augments β-blocker therapy in a mouse model of severe heart failure. *Proc Natl Acad Sci USA* 98, 5809–5814.

Hausdorff, W. P., Caron, M. G., & Lefkowitz, R. J. (1990). Turning off the signal: desensitization of β-adrenergic receptor function. *FASEB J* 4, 2881–2889.

Hebert, T. E., Moffett, S., Morello, J. P., Loisel, T. P., Bichet, D. G., Barret, C., et al. (1996). A peptide derived from a beta2-adrenergic receptor

transmembrane domain inhibits both receptor dimerization and activation. *J Biol Chem* 271, 16384–16392.

Hjalmarson, A., Goldstein, S., Fagerberg, B., Wedel, H., Waagstein, F., Kjekshus, J., et al. (2000). Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF study group. *JAMA* 283, 1295–1302.

Iwase, M., Bishop, S. P., Uechi, M., Vatner, D. E., Shannon, R. P., Kudej, R. K., et al. (1996). Adverse effects of chronic endogenous sympathetic drive induced by cardiac Gsα overexpression. *Circ Res* 78, 517–524.

Jahns, R., Boivin, V., Hein, L., Triebel, S., Angermann, C. E., Ertl, G., et al. (2004). Direct evidence for a β₁-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. *J Clin Invest* 113, 1419–1429.

Jo, S. H., Leblais, V., Wang, P. H., Crow, M. T., & Xiao, R. P. (2002). Phosphatidylinositol 3-kinase functionally compartmentalizes the concurrent Gs signaling during β₂-adrenergic stimulation. *Circ Res* 91, 46–53.

Jones, K. A., Borowsky, B., Tamm, J. A., Craig, D. A., Durkin, M. M., Dai, M., et al. (1998). GABAB receptors function as a heteromeric assembly of the subunits GABABR1 and GABABR2. *Nature* 396, 674–679.

Kass, D. A. (2003). β-Receptor polymorphisms: heart failure’s crystal ball. *Nat Med* 9, 1260–1262.

Kaumann, A. J., Sanders, L., Lynham, J. A., Bartel, S., Kuschel, M., Karczewski, P., et al. (1996). β₂-Adrenoceptor activation by zinterol causes protein phosphorylation, contractile effects and relaxant effects through a cAMP pathway in human atrium. *Mol Cell Biochem* 163–164, 113–123.

Kaumann, A. J., Hall, J. A., Murray, K. J., Wells, F. C., & Brown, M. J. (1998). A comparison of the effects of adrenaline and noradrenaline on human heart: the role of β₁- and β₂-adrenoceptors in the stimulation of adenylate cyclase and contractile force. *Eur Heart J* 10(Suppl B), 29–37.

Kaumann, A., Bartel, S., Molenaar, P., Sanders, L., Burrell, K., Vetter, D., et al. (1999). Activation of β₂-adrenergic receptors hastens relaxation and mediates phosphorylation of phospholamban, troponin I, and C-protein in ventricular myocardium from patients with terminal heart failure. *Circulation* 99, 65–72.

Kilts, J. D., Gerhardt, M. A., Richardson, M. D., Sreeram, G., Mackensen, G. B., Grocott, H. P., et al. (2000). β₂-Adrenergic and several other G protein-coupled receptors in human atrial membranes activate both Gs and Gi. *Circ Res* 87, 705–709.

Kirstein, S. L., & Insel, P. A. (2004). Autonomic nervous system pharmacogenomics: a progress report. *Pharmacol Rev* 56, 31–52.

Kiuchi, K., Shannon, R. P., Komamura, K., Cohen, D. J., Bianchi, C., Homcy, C. J., et al. (1993). Myocardial β-adrenergic receptor function during the development of pacing-induced heart failure. *J Clin Invest* 91, 907–914.

Koch, W. J., Rockman, H. A., Samama, P., Hamilton, R. A., Bond, R. A., Milano, C. A., et al. (1995). Cardiac function in mice overexpressing the β-adrenergic receptor kinase or a βARK inhibitor. *Science* 268, 1350–1353.

Kompa, A. R., Gu, X. H., Evans, B. A., & Summers, R. J. (1999). Desensitization of cardiac β-adrenoceptor signaling with heart failure produced by myocardial infarction in the rat. Evidence for the role of Gi but not Gs or phosphorylating proteins. *J Mol Cell Cardiol* 31, 1185–1201.

Korzick, D. H., Xiao, R. P., Ziman, B. D., Koch, W. J., Lefkowitz, R. J., & Lakatta, E. G. (1997). Transgenic manipulation of beta-adrenergic receptor kinase modifies cardiac myocyte contraction to norepinephrine. *Am J Physiol* 272, H590–H596.

Krum, H., Sackner-Bernstein, J. D., Goldsmith, R. L., Kukin, M. L., Schwartz, B., Penn, J., et al. (1995). Double-blind, placebo-controlled

study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. *Circulation* 92, 1499–1506.

Kuschel, M., Zhou, Y. Y., Cheng, H., Zhang, S. J., Chen, Y., Lakatta, E. G., et al. (1999a). Gi protein-mediated functional compartmentalization of cardiac β₂-adrenergic signaling. *J Biol Chem* 274, 22048–22052.

Kuschel, M., Zhou, Y. Y., Spurgeon, H. A., Bartel, S., Karczewski, P., Zhang, S. J., et al. (1999b). β₂-Adrenergic cAMP signaling is uncoupled from phosphorylation of cytoplasmic proteins in canine heart. *Circulation* 99, 2458–2465.

Kuznetsov, V., Pak, E., Robinson, R. B., & Steinberg, S. F. (1995). β₂-Adrenergic receptor actions in neonatal and adult rat ventricular myocytes. *Circ Res* 76, 40–52.

Lands, A. M., Arnold, A., McAuliff, J. P., Luduena, F. P., & Brown, T. G. (1967). Differentiation of receptor systems activated by sympathomimetic amines. *Nature* 214, 596–598.

Lavoie, C., & Hebert, T. E. (2003). Pharmacological characterization of putative β₁–β₂-adrenergic receptor heterodimers. *Can J Physiol Pharmacol* 81, 186–195.

Lavoie, C., Mercier, J. F., Salahpour, A., Umapathy, D., Breit, A., Villeneuve, L. R., et al. (2002). β₁/β₂-Adrenergic receptor heterodimerization regulates β₂-adrenergic receptor internalization and ERK signaling efficacy. *J Biol Chem* 277, 35402–35410.

Leineweber, K., Buscher, R., Bruck, H., & Brodde, O. E. (2004). β-Adrenoceptor polymorphisms. *Naunyn Schmiedebergs Arch Pharmacol* 369, 1–22.

Liao, P., Georgakopoulos, D., Kovacs, A., Zheng, M., Lerner, D., Pu, H., et al. (2001). The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. *Proc Natl Acad Sci USA* 98, 12283–12288.

Liggett, S. B., Wagoner, L. E., Craft, L. L., Hornung, R. W., Hoit, B. D., McIntosh, T. C., et al. (1998). The Ile164 β₂-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. *J Clin Invest* 102, 1534–1539.

Liggett, S. B., Tepe, N. M., Lorenz, J. N., Canning, A. M., Jantz, T. D., Mitarai, S., et al. (2000). Early and delayed consequences of β₂-adrenergic receptor overexpression in mouse hearts: critical role for expression level. *Circulation* 101, 1707–1714.

Limas, C. J., Goldenberg, I. F., & Limas, C. (1989). Autoantibodies against β-adrenoceptors in human idiopathic dilated cardiomyopathy. *Circ Res* 64, 97–103.

Lohse, M. J., Engelhardt, S., & Eschenhagen, T. (2003). What is the role of beta-adrenergic signaling in heart failure? *Circ Res* 93, 896–906.

Mason, D. A., Moore, J. D., Green, S. A., & Liggett, S. B. (1999). A gain-of-function polymorphism in a G-protein coupling domain of the human β₁-adrenergic receptor. *J Biol Chem* 274, 12670–12674.

Mercier, J. F., Salahpour, A., Angers, S., Breit, A., & Bouvier, M. (2002). Quantitative assessment of β₁- and β₂-adrenergic receptor homo- and heterodimerization by bioluminescence resonance energy transfer. *J Biol Chem* 277, 44925–44931.

MERIT-HF Study Group (1999). Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). *Lancet* 353, 2001–2007.

Mitra, M., Nardi, M., Giubbini, R., & Dei Cas, L. (1994). Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. *J Am Coll Cardiol* 24, 1678–1687.

Mitra, M., Giubbini, R., Nodari, S., Boldi, E., Modena, M. G., & Dei Cas, L. (2000). Differential effects of β-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. *Circulation* 102, 546–551.

Mialet Perez, J., Rathz, D. A., Petrashevskaya, N. N., Hahn, H. S., Wagoner, L. E., Schwartz, A., et al. (2003). β₁-Adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. *Nat Med* 9, 1300–1305.

Milano, C. A., Allen, L. F., Rockman, H. A., Dolber, P. C., McMinn, T. R., Chien, K. R., et al. (1994). Enhanced myocardial function in transgenic mice overexpressing the β₂-adrenergic receptor. *Science* 264, 582–586.

Moniotte, S., Kobzik, L., Feron, O., Trochu, J. N., Gauthier, C., & Balligand, J. L. (2001). Upregulation of β₃-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. *Circulation* 103, 1649–1655.

Morimoto, A., Hasegawa, H., Cheng, H. J., Little, W. C., & Cheng, C. P. (2004). Endogenous β₃-adrenoreceptor activation contributes to left ventricular and cardiomyocyte dysfunction in heart failure. *Am J Physiol Heart Circ Physiol* 286, H2425–H2433.

Morisco, C., Zebrowski, D., Condorelli, G., Tsichlis, P., Vatner, S. F., & Sadoshima, J. (2000). The Akt-glycogen synthase kinase 3β pathway regulates transcription of atrial natriuretic factor induced by β-adrenergic receptor stimulation in cardiac myocytes. *J Biol Chem* 275, 14466–14475.

Morita, H., Suzuki, G., Mishima, T., Chaudhry, P. A., Anagnostopoulos, P. V., Tanhehco, E. J., et al. (2002). Effects of long-term monotherapy with metoprolol CR/XL on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. *Cardiovasc Drugs Ther* 16, 443–449.

Nakano, A., Baines, C. P., Kim, S. O., Pelech, S. L., Downey, J. M., Cohen, M. V., et al. (2000). Ischemic preconditioning activates MAPKAPK2 in the isolated rabbit heart: evidence for involvement of p38 MAPK. *Circ Res* 86, 144–151.

Nienaber, J. J., Tachibana, H., Naga Prasad, S. V., Esposito, G., Wu, D., Mao, L., et al. (2003). Inhibition of receptor-localized PI3K preserves cardiac β-adrenergic receptor function and ameliorates pressure overload heart failure. *J Clin Invest* 112, 1067–1079.

O'Donnell, S. R., & Wanstall, J. C. (1980). Evidence that ICI 118, 551 is a potent, highly β₂-selective adrenoceptor antagonist and can be used to characterize β-adrenoceptor populations in tissues. *Life Sci* 27, 671–677.

Olsen, S. L., Gilbert, E. M., Renlund, D. G., Taylor, D. O., Yanowitz, F. D., & Bristow, M. R. (1995). Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. *J Am Coll Cardiol* 25, 1225–1231.

Patterson, A. J., Zhu, W., Chow, A., Agrawal, R., Kosek, J., Xiao, R. P., et al. (2004). Protecting the myocardium: a role for the β₂-adrenergic receptor in the heart. *Crit Care Med* 32, 1041–1048.

Poole-Wilson, P. A., Swedberg, K., Cleland, J. G., DiLenarda, A., Hanrath, P., Komajda, M., et al. (2003). Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. *Lancet* 362, 7–13.

Reiken, S., Gaburjakova, M., Gaburjakova, J., He, K. L., Prieto, A., Becker, E., et al. (2001). β-Adrenergic receptor blockers restore cardiac calcium release channel (ryanodine receptor) structure and function in heart failure. *Circulation* 104, 2843–2848.

Reiken, S., Wehrens, X. H., Vest, J. A., Barbone, A., Klotz, S., Mancini, D., et al. (2003). β-Blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. *Circulation* 107, 2459–2466.

Rockman, H. A., Chien, K. R., Choi, D. J., Iaccarino, G., Hunter, J. J., Ross Jr., J., et al. (1998). Expression of a β-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. *Proc Natl Acad Sci U S A* 95, 7000–7005.

Rohrer, D. K., Desai, K. H., Jasper, J. R., Stevens, M. E., Regula, D. J., Barsh, G. S., et al. (1996). Targeted disruption of the mouse β₁-adrenergic receptor gene: developmental and cardiovascular effects. *Proc Natl Acad Sci U S A* 93, 7375–7380.

Rohrer, D. K., Chruscinski, A., Schauble, E. H., Bernstein, D., & Kobilka, B. K. (1999). Cardiovascular and metabolic alterations in mice lacking both β₁- and β₂-adrenergic receptors. *J Biol Chem* 274, 16701–16708.

Roth, D. M., Bayat, H., Drumm, J. D., Gao, M. H., Swaney, J. S., Ander, A., et al. (2002). Adenylyl cyclase increases survival in cardiomyopathy. *Circulation* 105, 1989–1994.

Sato, M., Gong, H., Terracciano, C. M., Ranu, H., & Harding, S. E. (2004). Loss of β-adrenoceptor response in myocytes overexpressing the Na⁺/Ca²⁺-exchanger. *J Mol Cell Cardiol* 36, 43–48.

Shizukuda, Y., & Buttrick, P. M. (2002). Subtype specific roles of β-adrenergic receptors in apoptosis of adult rat ventricular myocytes. *J Mol Cell Cardiol* 34, 823–831.

Small, K. M., McGraw, D. W., & Liggett, S. B. (2003). Pharmacology and physiology of human adrenergic receptor polymorphisms. *Annu Rev Pharmacol Toxicol* 43, 381–411.

Sugden, P. H., & Clerk, A. (1998). “Stress-responsive” mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. *Circ Res* 83, 345–352.

Tachibana, H., Naga Prasad, S. V., Lefkowitz, R. J., Koch, W. J., & Rockman, H. A. (2005). Level of β-adrenergic receptor kinase 1 inhibition determines degree of cardiac dysfunction after chronic pressure overload-induced heart failure. *Circulation* 111, 591–597.

Tepe, N. M., Lorenz, J. N., Yatani, A., Dash, R., Kranias, E. G., Dorn II, G. W., et al. (1999). Altering the receptor-effector ratio by transgenic overexpression of type V adenylyl cyclase: enhanced basal catalytic activity and function without increased cardiomyocyte β-adrenergic signaling. *Biochemistry* 38, 16706–16713.

The Cardiac Insufficiency Bisoprolol Study II (CIBIC II) (1999). The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomized trial. *Lancet* 353, 9–13.

Turki, J., Lorenz, J. N., Green, S. A., Bonnelly, E. T., Jacinto, M., & Liggett, S. B. (1996). Myocardial signaling defects and impaired cardiac function of a human β₂-adrenergic receptor polymorphism expressed in transgenic mice. *Proc Natl Acad Sci U S A* 93, 10483–10488.

Ungerer, M., Parruti, G., Bohm, M., Puzicha, M., DeBlasi, A., Erdmann, E., et al. (1994). Expression of β-arrestins and β-adrenergic receptor kinases in the failing human heart. *Circ Res* 74, 206–213.

Vatner, D. E., Yang, G. P., Geng, Y. J., Asai, K., Yun, J. S., Wagner, T. E., et al. (2000). Determinants of the cardiomyopathic phenotype in chimeric mice overexpressing cardiac Gsα. *Circ Res* 86, 802–806.

Wang, W., Zhu, W., Wang, S., Yang, D., Crow, M. T., Xiao, R. P., et al. (2004). Sustained β₁-adrenergic stimulation modulates cardiac contractility by Ca²⁺/calmodulin kinase signaling pathway. *Circ Res* 95, 798–806.

Williams, M. L., Hata, J. A., Schroder, J., Rampersaud, E., Petrofski, J., Jakoi, A., et al. (2004). Targeted β-adrenergic receptor kinase (βARK1) inhibition by gene transfer in failing human hearts. *Circulation* 109, 1590–1593.

Wright, S. C., Schellenberger, U., Ji, L., Wang, H., & Larrick, J. W. (1997). Calmodulin-dependent protein kinase II mediates signal transduction in apoptosis. *FASEB J* 11, 843–849.

Xiao, R. P., & Balke, C. W. (2004). Na⁺/Ca²⁺ exchange linking β₂-adrenergic Gi signaling to heart failure: associated defect of adrenergic contractile support. *J Mol Cell Cardiol* 36, 7–11.

Xiao, R. P., Hohl, C., Altschuld, R., Jones, L., Livingston, B., Ziman, B., et al. (1994). β₂-Adrenergic receptor-stimulated increase in cAMP in rat heart cells is not coupled to changes in Ca²⁺ dynamics, contractility, or phospholamban phosphorylation. *J Biol Chem* 269, 19151–19156.

Xiao, R. P., Ji, X., & Lakatta, E. G. (1995). Functional coupling of the β₂-adrenergic receptor to a pertussis toxin-sensitive G protein in cardiac myocytes. *Mol Pharmacol* 47, 322–329.

Xiao, R. P., Tomhave, E. D., Wang, D. J., Ji, X., Boluyt, M. O., Cheng, H., et al. (1998). Age-associated reductions in cardiac β₁- and β₂-adrenergic responses without changes in inhibitory G proteins or receptor kinases. *J Clin Invest* 101, 1273–1282.

Xiao, R. P., Avdonin, P., Zhou, Y. Y., Cheng, H., Akhter, S. A., Eschenhagen, T., et al. (1999). Coupling of β₂-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes. *Circ Res* 84, 43–52.

Xiao, R. P., Zhang, S. J., Chakir, K., Avdonin, P., Zhu, W., Bond, R., et al. (2003). Enhanced Gi signaling selectively negates β₂-adrenergic receptor (AR)-but not β₁-AR-mediated positive inotropic effect in myocytes from failing rat hearts. *Circulation* 108, 1633–1639.

Zaugg, M., Xu, W., Lucchinetti, E., Shafiq, S. A., Jamali, N. Z., & Siddiqui, M. A. (2000). β-Adrenergic receptor subtypes differentially affect apoptosis in adult rat ventricular myocytes. *Circulation* 102, 344–350.

Zhang, T., Maier, L. S., Dalton, N. D., Miyamoto, S., Ross Jr., J., Bers, D. M., et al. (2003). The δC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. *Circ Res* 92, 912–919.

Zhang, R., Khoo, M. S., Wu, Y., Yang, Y., Grueter, C. E., Ni, G., et al. (2005). Calmodulin kinase II inhibition protects against structural heart disease. *Nat Med* 11, 409–417.

Zheng, M., Reynolds, C., Jo, S. H., Robert, W., Han, Q., & Xiao, R. P. (2005). Intracellular acidosis-activated p38 MAPK signaling and its essential role in cardiomyocyte hypoxic injury. *FASEB J* 19, 109–111.

Zhou, Y. Y., Cheng, H., Bogdanov, K. Y., Hohl, C., Altschuld, R., Lakatta, E. G., et al. (1997). Localized cAMP-dependent signaling mediates β₂-adrenergic modulation of cardiac excitation–contraction coupling. *Am J Physiol Heart Circ Physiol* 273, H1611–H1618.

Zhu, W. Z., Zheng, M., Koch, W. J., Lefkowitz, R. J., Kobilka, B. K., & Xiao, R. P. (2001). Dual modulation of cell survival and cell death by β₂-adrenergic signaling in adult mouse cardiac myocytes. *Proc Natl Acad Sci U S A* 98, 1607–1612.

Zhu, W. Z., Wang, S. Q., Chakir, K., Yang, D., Zhang, T., Brown, J. H., et al. (2003). Linkage of β₁-adrenergic stimulation to apoptotic heart cell death through protein kinase A-independent activation of Ca²⁺/calmodulin kinase. *J Clin Invest* 111, 617–625.

Zou, Y., Komuro, I., Yamazaki, T., Kudoh, S., Uozumi, H., Kadowaki, T., et al. (1999). Both Gₛ and Gᵢ proteins are critically involved in isoproterenol-induced cardiomyocyte hypertrophy. *J Biol Chem* 274, 9760–9770.
